(2S)-3-(氨基甲酰氨基)-2-({[(9H-芴-9-基)甲氧基]羰基}氨基)丙酸 | 1192601-91-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: (2S)-3-(氨基甲酰氨基)-2-({[(9H-芴-9-基)甲氧基]羰基}氨基)丙酸
• 英文名称: Fmoc-l-2-amino-3-ureidopropionic acid
• 英文别名: (2S)-3-(carbamoylamino)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
• CAS: 1192601-91-4
• 化学式: C₁₉H₁₉N₃O₅
• 分子量: 369.4
• InChiKey: XSICSLZBMDMQRC-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  131
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• [EN] PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII<br/>[FR] MACROCYCLES PEPTIDIQUES CONTRE ACINETOBACTER BAUMANNII
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017072062A1

  公开（公告）日：2017-05-04

  The present invention provides compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.

  本发明提供了式（I）的化合物，其中X1至X8和R1至R8如本文所述，以及其药学上可接受的盐。此外，本发明涉及制备式（I）的化合物，包括它们的药物组合物以及它们作为治疗由鲍曼不动杆菌引起的疾病和感染的药物的用途。
• Peptide macrocycles against acinetobacter baumannii
  申请人：Hoffmann-La Roche Inc.

  公开号：US10030047B2

  公开（公告）日：2018-07-24

  The present invention provides compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.

  本发明提供了式 (I) 的化合物 其中 X1 至 X8 和 R1 至 R8 如本文所述，以及其药学上可接受的盐。此外，本发明还涉及式（I）化合物的制造、包含它们的药物组合物以及它们作为治疗鲍曼不动杆菌引起的疾病和感染的药物的用途。
• Thrombospondin 1-binding peptide
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US11149066B2

  公开（公告）日：2021-10-19

  Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia. Specifically provided is a macrocyclic polypeptide represented by formula (I) [wherein A is selected from the linking groups A1 to A6; Xaa1 is a residue of an aliphatic amino acid, an aromatic amino acid, a basic amino acid, a neutral amino acid, or an acidic amino acid, or is absent; Xaa2 is a residue of an aromatic amino acid or a neutral amino acid; Xaa3 is a residue of an aliphatic amino acid, an aromatic amino acid, or a basic amino acid; Xaa4 is Ser, Thr, Ala, or mS; Xaa5 is Gly or Ser; Xaa6 is a residue of a basic amino acid or a neutral amino acid; Xaa7 is a residue of a neutral amino acid or an acidic amino acid; Xaa8 is a residue of an aromatic amino acid; Xaa9 is a residue of an aliphatic amino acid, a neutral amino acid, or an aromatic amino acid; Xaa10 is a residue of a basic amino acid, an aliphatic amino acid, an aromatic amino acid, or a neutral amino acid; Xaa11 is a residue of an aromatic amino acid; and Xaa12 is a residue of an aliphatic amino acid, an aromatic amino acid, or a basic amino acid], or a pharmacologically acceptable salt thereof.

  本发明提供了一种化合物，该化合物可通过抑制 TSP1 的功能促进血管生成，并可用于治疗或预防危重肢体缺血等疾病。 具体而言，提供了一种由式（I）代表的大环多肽 [其中 A 选自连接基团 A1 至 A6；Xaa1 是脂肪族氨基酸、芳香族氨基酸、碱性氨基酸、中性氨基酸或酸性氨基酸的残基，或者不存在；Xaa2 是芳香族氨基酸或中性氨基酸的残基；Xaa3 是脂肪族氨基酸、芳香族氨基酸或碱性氨基酸的残基； Xaa4 是 Ser、Thr、Ala 或 mS； Xaa5 是 Gly 或 Ser； Xaa6 是碱性氨基酸或中性氨基酸的残基；Xaa7 是中性氨基酸或酸性氨基酸的残基； Xaa8 是芳香族氨基酸的残基； Xaa9 是脂肪族氨基酸、中性氨基酸或芳香族氨基酸的残基；Xaa10 是碱性氨基酸、脂肪族氨基酸、芳香族氨基酸或中性氨基酸的残基； Xaa11 是芳香族氨基酸的残基；以及 Xaa12 是脂肪族氨基酸、芳香族氨基酸或碱性氨基酸的残基]，或其药理学上可接受的盐。
• PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3368544B1

  公开（公告）日：2020-06-17
• THROMBOSPONDIN 1-BINDING PEPTIDE
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20200131230A1

  公开（公告）日：2020-04-30

  Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia. Specifically provided is a macrocyclic polypeptide represented by formula (I) [wherein A is selected from the linking groups A 1 to A 6 ; X aa1 is a residue of an aliphatic amino acid, an aromatic amino acid, a basic amino acid, a neutral amino acid, or an acidic amino acid, or is absent; X aa2 is a residue of an aromatic amino acid or a neutral amino acid; X aa3 is a residue of an aliphatic amino acid, an aromatic amino acid, or a basic amino acid; X aa4 is Ser, Thr, Ala, or m S; X aa5 is Gly or Ser; X aa6 is a residue of a basic amino acid or a neutral amino acid; X aa7 is a residue of a neutral amino acid or an acidic amino acid; X aa8 is a residue of an aromatic amino acid; X aa9 is a residue of an aliphatic amino acid, a neutral amino acid, or an aromatic amino acid; X aa10 is a residue of a basic amino acid, an aliphatic amino acid, an aromatic amino acid, or a neutral amino acid; X aa11 is a residue of an aromatic amino acid; and X aa12 is a residue of an aliphatic amino acid, an aromatic amino acid, or a basic amino acid], or a pharmacologically acceptable salt thereof.